GLP-1 and Sleep Apnea: The SURMOUNT-OSA Breakthrough

For the estimated 30 million Americans living with obstructive sleep apnea, the standard prescription has long been the same: strap on a CPAP machine every night, for the rest of your life. But in 2024, a landmark clinical trial rewrote that conversation. Tirzepatide — the dual GIP/GLP-1 receptor agonist marketed as Zepbound for weight loss — produced such dramatic reductions in sleep apnea severity that the FDA granted it an entirely new indication. Here's what the SURMOUNT-OSA trial found, what it means for patients, and why the obesity-sleep apnea connection is more central than most people realize.

The Obesity–Sleep Apnea Link: Why Weight Is the Root Cause

Obstructive sleep apnea (OSA) occurs when the upper airway partially or fully collapses during sleep, causing repeated cessations in breathing — often dozens or hundreds of times per night. Each episode triggers a micro-arousal that fragments sleep architecture and drives a cascade of consequences: daytime sleepiness, impaired cognition, hypertension, cardiovascular disease, metabolic dysfunction, and increased all-cause mortality.

Obesity is the single largest modifiable risk factor for OSA. Excess adipose tissue in the neck, throat, and tongue increases the mechanical load on the airway. Fat deposits around the chest wall reduce lung volumes, lowering the "tracheal tug" that helps keep the upper airway open. Visceral obesity also generates systemic inflammation that impairs respiratory muscle control and chemoreceptor sensitivity.

The relationship is dose-dependent: a 10% increase in body weight is associated with a roughly 32% increase in AHI (apnea-hypopnea index — the number of breathing disruptions per hour), while a 10% weight loss typically reduces AHI by 26%. This mechanistic link is why researchers hypothesized that powerful obesity medications might treat sleep apnea not as a side effect, but as a primary therapeutic target.

SURMOUNT-OSA: The Trial That Changed Everything

SURMOUNT-OSA was a phase 3, double-blind, randomized, placebo-controlled trial conducted across two parallel cohorts of adults with moderate-to-severe OSA and obesity. The results were published in The New England Journal of Medicine in June 2024 (Malhotra A, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." NEJM. 2024;391:1-13).

Study Design

The trial enrolled 469 adults with a BMI ≥30 kg/m² and moderate-to-severe OSA (AHI ≥15 events/hour). Participants were divided into two cohorts:

• Cohort 1: Participants not using CPAP who either declined or could not tolerate CPAP therapy (n=234)
• Cohort 2: Participants using CPAP who agreed to discontinue use for the study (n=235)

Participants received tirzepatide (dose-escalated to 10 or 15 mg weekly) or placebo for 52 weeks. The primary endpoint was change in AHI from baseline.

The Results: 55–63% AHI Reduction

The findings were extraordinary by any standard in sleep medicine:

• Cohort 1 (no CPAP): Tirzepatide reduced AHI by a mean of 27.4 events/hour, a 55.0% reduction from baseline (placebo: 4.8 events/hour reduction, 5.2%)
• Cohort 2 (former CPAP users): Tirzepatide reduced AHI by 30.4 events/hour, a 62.8% reduction (placebo: 6.0 events/hour, 9.7%)
• In Cohort 1, 42.5% of tirzepatide participants achieved OSA resolution (AHI <5) vs. 15.8% on placebo
• Mean body weight loss was approximately 18–20% in tirzepatide groups vs. ~2% in placebo
• Secondary endpoints — hypoxic burden, PROMIS sleep disturbance score, systolic blood pressure, and C-reactive protein — all improved significantly with tirzepatide

To put those numbers in context: CPAP therapy is the gold standard for OSA precisely because it eliminates apneas mechanically — yet it doesn't treat the underlying cause, and up to 50% of patients struggle with adherence. Tirzepatide produced AHI reductions in the 55–63% range while also generating benefits CPAP cannot offer, including weight loss, metabolic improvement, and lower blood pressure.

FDA Approval: A New Era for Sleep Apnea Treatment

In June 2024, the FDA approved tirzepatide (Zepbound) for a new indication: the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. This made Zepbound the first and only prescription medication approved to treat OSA — a milestone in a field that had been mechanically focused for decades.

The approval was specifically for OSA in patients with obesity, reflecting the mechanistic rationale: tirzepatide treats OSA by reducing the obesity that drives it, rather than by direct airway manipulation. This is a fundamentally different — and in many cases more durable — approach than CPAP.

What About Semaglutide and Other GLP-1s?

Questions naturally arise about whether semaglutide (Ozempic/Wegovy) produces similar benefits for OSA. While no dedicated OSA trial of semaglutide has matched the scale of SURMOUNT-OSA, the SELECT cardiovascular outcomes trial — which enrolled 17,604 adults with obesity and cardiovascular disease — did capture sleep apnea as a secondary endpoint and showed significant AHI improvements in the semaglutide arm. Given semaglutide's similar weight loss mechanism, the benefits are biologically plausible and clinically observed in practice.

The distinction is that tirzepatide's dual GIP/GLP-1 mechanism produces approximately 20–22% average weight loss in trials versus 15% for semaglutide — and more weight loss appears to translate to more AHI reduction. Tirzepatide's OSA-specific FDA approval reflects both the magnitude of its effect and the quality of the dedicated trial data.

Is This a CPAP Replacement?

For patients with obesity-driven OSA, tirzepatide represents a meaningful addition to — and in some cases a potential alternative to — CPAP, particularly for the large population of CPAP-intolerant or CPAP-refusing patients. It is not a universal OSA treatment: patients with anatomical causes of airway obstruction (e.g., enlarged tonsils, jaw structure issues) or non-obese OSA may not benefit as substantially from weight loss-mediated approaches.

Current clinical guidance generally recommends that patients currently on CPAP not discontinue it unilaterally without a repeat sleep study, even if they achieve significant weight loss. Post-weight-loss sleep testing often reveals dramatically improved or resolved OSA — at which point CPAP can be appropriately discontinued with physician guidance.

The Bigger Picture: GLP-1s and Comorbidity Cascade

SURMOUNT-OSA is the most prominent example of a broader pattern emerging in GLP-1 research: these medications don't just reduce weight — they systematically reduce the weight-related comorbidity burden. Alongside OSA, tirzepatide and semaglutide have now demonstrated benefits in cardiovascular disease (SELECT trial: 20% reduction in MACE), heart failure with preserved ejection fraction (STEP-HFpEF), non-alcoholic steatohepatitis (NASH), chronic kidney disease, and type 2 diabetes remission.

The clinical implication is profound: treating obesity with these medications may simultaneously address five to seven conditions that individually carry significant morbidity and mortality — shifting the conversation from "weight loss medication" to "metabolic disease intervention."

Who Should Consider GLP-1 Therapy for Sleep Apnea?

Based on current evidence and the FDA approval, candidates may include adults with a BMI ≥30 kg/m² (or ≥27 with a weight-related comorbidity) who also have confirmed moderate-to-severe OSA. A formal sleep study is the starting point for OSA diagnosis, and a comprehensive medical evaluation is necessary before initiating any GLP-1 therapy. The decision involves weighing benefits, risks, cost, insurance coverage, and individual health history with a knowledgeable provider.